Quantcast

Industry news that matters to you.  Learn more

Amarantus BioSciences Licenses Parkinson’s Disease Diagnostic Biomarker Test from Power3 Medical Products

Amarantus BioSciences, Inc., a biotechnology company developing MANF, a first-inclass disease–modifying therapeutic protein being developed for the treatment of Parkinson’s Disease, today announced an exclusive worldwide license agreement with Power3 Medical Products, Inc. for the NuroPro Blood Test as it relates to Parkinson’s disease diagnosis. Concurrent with the license, Amarantus has raised $100,000 from a private, foreign investor introduced to the Company by www.tomorrowsbluechips.com.

Power3 Medical to Publish Medical Breakthrough Documented During Clinical Trials of Power3 Medical’s Flag Ship NuroPro(R) Diagnostic

Power3 Medical Products, Inc. (OTCBB: PWRM – News) announced today that, in collaboration with Lourdes R. Bosquez, MD, it has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro® protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept® (Donepezil HCl, Pfizer – NYSE: PFE), Exelon® (Rivastigmine, Novartis – NYSE: NVS), and Namenda® (Memantine HCl, Forest Laboratories – NYSE: FRX). These results relate to the genetically distinct groups of Alzheimer’s disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene.